IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.426
AS - Asia 2.705
EU - Europa 2.012
SA - Sud America 292
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 4
Totale 8.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.351
CN - Cina 1.527
SG - Singapore 563
IE - Irlanda 516
UA - Ucraina 370
DE - Germania 273
FI - Finlandia 246
HK - Hong Kong 225
BR - Brasile 210
RU - Federazione Russa 184
VN - Vietnam 163
FR - Francia 105
SE - Svezia 102
IT - Italia 89
IN - India 63
GB - Regno Unito 59
CA - Canada 42
ZA - Sudafrica 33
AR - Argentina 25
IQ - Iraq 24
BD - Bangladesh 22
NL - Olanda 15
MX - Messico 14
TR - Turchia 14
EC - Ecuador 13
PL - Polonia 12
CL - Cile 11
JO - Giordania 11
VE - Venezuela 11
PK - Pakistan 10
UZ - Uzbekistan 10
JP - Giappone 9
SA - Arabia Saudita 9
ES - Italia 8
LT - Lituania 8
MA - Marocco 8
PH - Filippine 8
BO - Bolivia 7
CO - Colombia 7
ID - Indonesia 6
IR - Iran 6
MY - Malesia 6
EG - Egitto 5
NP - Nepal 5
AL - Albania 4
CR - Costa Rica 4
EU - Europa 4
KE - Kenya 4
NI - Nicaragua 4
PY - Paraguay 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
GE - Georgia 3
NZ - Nuova Zelanda 3
PA - Panama 3
AT - Austria 2
AZ - Azerbaigian 2
BB - Barbados 2
CY - Cipro 2
DZ - Algeria 2
GR - Grecia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
RO - Romania 2
UG - Uganda 2
AD - Andorra 1
AO - Angola 1
AU - Australia 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LS - Lesotho 1
MD - Moldavia 1
NG - Nigeria 1
SI - Slovenia 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 8.506
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
San Jose 415
Chandler 396
Nanjing 350
Singapore 263
Ashburn 251
Beijing 231
Hong Kong 218
Dallas 214
Nanchang 156
Boardman 149
Shenyang 121
Council Bluffs 108
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 100
Lawrence 95
Hebei 92
Medford 81
Lauterbourg 80
Tianjin 66
Los Angeles 62
Hangzhou 52
Ho Chi Minh City 44
Munich 39
Buffalo 38
Hanoi 38
Helsinki 38
New York 38
Redondo Beach 35
Johannesburg 31
Toronto 26
Santa Clara 25
Seattle 25
Shanghai 25
Moscow 24
Norwalk 22
São Paulo 21
Frankfurt am Main 18
Turku 18
Orem 16
Des Moines 14
Milan 13
Woodbridge 13
Fairfield 12
San Francisco 12
Atlanta 11
Jinan 11
Pune 11
Amman 10
Ann Arbor 10
Baghdad 10
Haiphong 9
Quito 9
Kunming 8
London 8
Montreal 8
Poplar 8
Tokyo 8
Warsaw 8
Chennai 7
Dearborn 7
Tashkent 7
Belo Horizonte 6
Brooklyn 6
Da Nang 6
Eindhoven 6
Lanzhou 6
Rio de Janeiro 6
Rome 6
Verona 6
Guangzhou 5
New Delhi 5
Ningbo 5
Taizhou 5
Washington 5
Amsterdam 4
Biên Hòa 4
Caracas 4
Casablanca 4
Chicago 4
Halifax 4
Istanbul 4
Jeddah 4
Managua 4
Manchester 4
Nairobi 4
Orange 4
Porto Alegre 4
Stockholm 4
Tehran 4
Zhengzhou 4
Bogotá 3
Boston 3
Brasília 3
Brussels 3
Bắc Giang 3
Bắc Ninh 3
Totale 5.699
Salva come PNG Salva come JPEG
Nome #
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 134
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 132
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 131
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 128
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 127
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 127
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 127
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 125
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 125
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 123
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 123
Comparison between orlistat and sibutramine in obese patients with mild hypertension 122
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 111
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 111
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 110
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 109
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 108
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 108
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 107
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 107
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 106
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 106
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 105
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 105
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 104
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 104
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 103
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 103
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 100
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 97
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 97
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 93
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 93
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 92
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 92
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 91
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 90
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 90
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 88
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 88
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 87
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 87
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 87
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 85
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 85
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 85
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 84
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 84
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 83
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 83
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 83
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 83
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 82
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 82
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 82
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 82
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 82
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 82
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 81
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 81
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 81
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 80
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 80
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 80
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 79
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 79
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 78
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 78
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 78
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 76
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 76
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 76
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 75
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 75
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 74
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 74
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 73
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 73
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 72
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 72
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 71
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 71
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 71
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 70
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 70
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 69
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 69
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 67
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 66
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 64
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 63
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 63
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 61
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 60
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 51
Totale 8.527
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.094
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.094
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/20251.068 8 107 46 37 10 31 61 77 262 6 115 308
2025/20262.564 261 175 261 217 267 118 559 112 238 217 86 53
2026/2027150 40 110 0 0 0 0 0 0 0 0 0 0
Totale 8.527